This Iplex market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historical period can be attributed to factors such as the rising prevalence of growth disorders, increasing awareness of growth-related conditions, higher healthcare expenditure, greater investment in research and development, and supportive government policies.
Market growth during the forecast period expected to be driven by the expanding pediatric population, the rising costs of treating growth hormone deficiencies, the increase in counterfeit products for growth hormone deficiency treatment, a growing geriatric population, and rising government initiatives. Key trends in the forecast period include a greater focus on orphan drug development, advancements in recombinant protein technology, wider adoption of personalized medicine approaches, growth in telemedicine for pediatric endocrinology, and the expansion of clinical trials in emerging markets.
The increasing prevalence of growth hormone deficiencies (GHD) is expected to drive the expansion of the iplex market. GHD is a condition where the pituitary gland fails to produce enough growth hormone, leading to growth and developmental issues in both children and adults. The rising incidence of GHD is attributed to better diagnostic techniques, greater awareness of endocrine disorders, and the increased prevalence of conditions such as genetic mutations, tumors, or traumatic brain injuries that can hinder growth hormone production. Iplex (mecasermin rinfabate) treats GHD by providing insulin-like growth factor-1 (IGF-1) combined with IGF-binding protein-3 to stimulate growth and metabolic activity. For instance, in May 2022, the National Institutes of Health (NIH) estimated that the prevalence of GHD is approximately 2 to 3 cases per 10,000 individuals. This growing incidence of GHD is expected to contribute to the growth of the iplex market.
The expanding pediatric population is expected to drive the growth of the iplex market. The pediatric population, which includes children from birth to 18 years, requires specialized care to support growth, development, and age-specific health needs. The growth of this population is driven by higher birth rates, improved healthcare reducing child mortality, and greater awareness of childhood health needs, leading to an increased demand for pediatric treatments and services. Iplex is particularly beneficial for children with GHD, offering targeted IGF-1 therapy to support growth and development, especially in cases where traditional treatments are ineffective. For example, in February 2024, the Australian Institute of Health Care and Welfare projected that the number of children in Australia would grow to 6.4 million by 2048. As a result, the expanding pediatric population is a significant driver of growth in the iplex market.
The growing investment in healthcare research and development is anticipated to boost the growth of the iplex market. Research and development in healthcare focus on discovering new treatments, enhancing existing therapies, and innovating technologies to improve patient care and public health outcomes. The increase in healthcare R&D investment is driven by the need for novel treatments, advancements in technology, and the rising burden of chronic and rare diseases, all of which ensure better healthcare outcomes and address unmet medical needs. These investments support the development and manufacturing of Iplex by funding innovation, improving treatment efficacy, and expanding production capabilities. For example, in July 2024, the Association of the British Pharmaceutical Industry (ABPI) reported an increase in R&D spending, with £467 million invested in R&D collaborations in 2023, up from £440.6 million in 2022 and £405.1 million in 2021 (approximately $585 million in 2023, $563 million in 2022, and $518 million in 2021). Consequently, the rising investment in healthcare research and development is driving the growth of the iplex market.
The key company operating in the iplex market is Insmed Incorporated.
North America was the largest region in the Iplex market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in iplex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the iplex market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Iplex (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF binding protein-3 (IGFBP-3). It is used to treat severe primary IGF-1 deficiency, promoting growth in children. By stabilizing IGF-1, it enhances cellular growth, metabolism, and development while minimizing the risk of hypoglycemia typically associated with free IGF-1.
The primary patient demographics for iplex include pediatric patients and other age groups. Pediatric patients, aged 0 to 18 years, require specialized medical care to support growth and development. Iplex is used in these patients to address growth hormone deficiencies by providing targeted IGF-1 therapy, ensuring proper growth when traditional treatments are ineffective. The drug is distributed through hospitals, retail pharmacies, specialty pharmacies, and online pharmacies, and is used for various conditions, including growth hormone deficiency and other related applications.
The iplex market research report is one of a series of new reports that provides iplex market statistics, including the iplex industry's global market size, regional shares, competitors with a iplex market share, detailed iplex market segments, market trends and opportunities, and any further data you may need to thrive in the iplex industry. This iplex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The iplex market consists of sales of mecasermin rinfabate (rDNA origin) injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historical period can be attributed to factors such as the rising prevalence of growth disorders, increasing awareness of growth-related conditions, higher healthcare expenditure, greater investment in research and development, and supportive government policies.
Market growth during the forecast period expected to be driven by the expanding pediatric population, the rising costs of treating growth hormone deficiencies, the increase in counterfeit products for growth hormone deficiency treatment, a growing geriatric population, and rising government initiatives. Key trends in the forecast period include a greater focus on orphan drug development, advancements in recombinant protein technology, wider adoption of personalized medicine approaches, growth in telemedicine for pediatric endocrinology, and the expansion of clinical trials in emerging markets.
The increasing prevalence of growth hormone deficiencies (GHD) is expected to drive the expansion of the iplex market. GHD is a condition where the pituitary gland fails to produce enough growth hormone, leading to growth and developmental issues in both children and adults. The rising incidence of GHD is attributed to better diagnostic techniques, greater awareness of endocrine disorders, and the increased prevalence of conditions such as genetic mutations, tumors, or traumatic brain injuries that can hinder growth hormone production. Iplex (mecasermin rinfabate) treats GHD by providing insulin-like growth factor-1 (IGF-1) combined with IGF-binding protein-3 to stimulate growth and metabolic activity. For instance, in May 2022, the National Institutes of Health (NIH) estimated that the prevalence of GHD is approximately 2 to 3 cases per 10,000 individuals. This growing incidence of GHD is expected to contribute to the growth of the iplex market.
The expanding pediatric population is expected to drive the growth of the iplex market. The pediatric population, which includes children from birth to 18 years, requires specialized care to support growth, development, and age-specific health needs. The growth of this population is driven by higher birth rates, improved healthcare reducing child mortality, and greater awareness of childhood health needs, leading to an increased demand for pediatric treatments and services. Iplex is particularly beneficial for children with GHD, offering targeted IGF-1 therapy to support growth and development, especially in cases where traditional treatments are ineffective. For example, in February 2024, the Australian Institute of Health Care and Welfare projected that the number of children in Australia would grow to 6.4 million by 2048. As a result, the expanding pediatric population is a significant driver of growth in the iplex market.
The growing investment in healthcare research and development is anticipated to boost the growth of the iplex market. Research and development in healthcare focus on discovering new treatments, enhancing existing therapies, and innovating technologies to improve patient care and public health outcomes. The increase in healthcare R&D investment is driven by the need for novel treatments, advancements in technology, and the rising burden of chronic and rare diseases, all of which ensure better healthcare outcomes and address unmet medical needs. These investments support the development and manufacturing of Iplex by funding innovation, improving treatment efficacy, and expanding production capabilities. For example, in July 2024, the Association of the British Pharmaceutical Industry (ABPI) reported an increase in R&D spending, with £467 million invested in R&D collaborations in 2023, up from £440.6 million in 2022 and £405.1 million in 2021 (approximately $585 million in 2023, $563 million in 2022, and $518 million in 2021). Consequently, the rising investment in healthcare research and development is driving the growth of the iplex market.
The key company operating in the iplex market is Insmed Incorporated.
North America was the largest region in the Iplex market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in iplex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the iplex market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Iplex (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF binding protein-3 (IGFBP-3). It is used to treat severe primary IGF-1 deficiency, promoting growth in children. By stabilizing IGF-1, it enhances cellular growth, metabolism, and development while minimizing the risk of hypoglycemia typically associated with free IGF-1.
The primary patient demographics for iplex include pediatric patients and other age groups. Pediatric patients, aged 0 to 18 years, require specialized medical care to support growth and development. Iplex is used in these patients to address growth hormone deficiencies by providing targeted IGF-1 therapy, ensuring proper growth when traditional treatments are ineffective. The drug is distributed through hospitals, retail pharmacies, specialty pharmacies, and online pharmacies, and is used for various conditions, including growth hormone deficiency and other related applications.
The iplex market research report is one of a series of new reports that provides iplex market statistics, including the iplex industry's global market size, regional shares, competitors with a iplex market share, detailed iplex market segments, market trends and opportunities, and any further data you may need to thrive in the iplex industry. This iplex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The iplex market consists of sales of mecasermin rinfabate (rDNA origin) injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Iplex Market Characteristics4. Iplex Market Trends and Strategies5. Iplex Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Iplex Pricing Analysis & Forecasts30. Global Iplex Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Iplex Market32. Recent Developments in the Iplex Market
3. Iplex Market Biologic Drug Characteristics
6. Global Iplex Growth Analysis and Strategic Analysis Framework
8. Iplex Market Segmentation
9. Global Iplex Epidemiology of Clinical Indications
10. Iplex Market Regional and Country Analysis
11. Asia-Pacific Iplex Market
12. China Iplex Market
13. India Iplex Market
14. Japan Iplex Market
15. Australia Iplex Market
16. South Korea Iplex Market
17. Western Europe Iplex Market
18. UK Iplex Market
19. Germany Iplex Market
20. France Iplex Market
21. Eastern Europe Iplex Market
22. North America Iplex Market
23. USA Iplex Market
24. Canada Iplex Market
25. South America Iplex Market
26. Middle East Iplex Market
27. Africa Iplex Market
28. Iplex Market Competitive Landscape and Company Profiles
29. Global Iplex Market Pipeline Analysis
33. Iplex Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Iplex Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on iplex market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for iplex? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The iplex market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Patient Demographics: Pediatric Patients; Age Groups2) by Distribution Channel: Hospitals; Retail Pharmacies; Specialty Pharmacies; Online Pharmacies
3) by Application: Growth Hormone Deficiency; Other Applications
Key Companies Mentioned: Insmed Incorporated
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Insmed Incorporated
